These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

950 related items for PubMed ID: 12472790

  • 1. The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism.
    Lindberg JS, Moe SM, Goodman WG, Coburn JW, Sprague SM, Liu W, Blaisdell PW, Brenner RM, Turner SA, Martin KJ.
    Kidney Int; 2003 Jan; 63(1):248-54. PubMed ID: 12472790
    [Abstract] [Full Text] [Related]

  • 2. The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease.
    Quarles LD, Sherrard DJ, Adler S, Rosansky SJ, McCary LC, Liu W, Turner SA, Bushinsky DA.
    J Am Soc Nephrol; 2003 Mar; 14(3):575-83. PubMed ID: 12595492
    [Abstract] [Full Text] [Related]

  • 3. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study.
    Lindberg JS, Culleton B, Wong G, Borah MF, Clark RV, Shapiro WB, Roger SD, Husserl FE, Klassen PS, Guo MD, Albizem MB, Coburn JW.
    J Am Soc Nephrol; 2005 Mar; 16(3):800-7. PubMed ID: 15689407
    [Abstract] [Full Text] [Related]

  • 4. Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl.
    Moe SM, Cunningham J, Bommer J, Adler S, Rosansky SJ, Urena-Torres P, Albizem MB, Guo MD, Zani VJ, Goodman WG, Sprague SM.
    Nephrol Dial Transplant; 2005 Oct; 20(10):2186-93. PubMed ID: 16030053
    [Abstract] [Full Text] [Related]

  • 5. The Calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism.
    Goodman WG, Hladik GA, Turner SA, Blaisdell PW, Goodkin DA, Liu W, Barri YM, Cohen RM, Coburn JW.
    J Am Soc Nephrol; 2002 Apr; 13(4):1017-1024. PubMed ID: 11912261
    [Abstract] [Full Text] [Related]

  • 6. The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism.
    Messa P, Macário F, Yaqoob M, Bouman K, Braun J, von Albertini B, Brink H, Maduell F, Graf H, Frazão JM, Bos WJ, Torregrosa V, Saha H, Reichel H, Wilkie M, Zani VJ, Molemans B, Carter D, Locatelli F.
    Clin J Am Soc Nephrol; 2008 Jan; 3(1):36-45. PubMed ID: 18178780
    [Abstract] [Full Text] [Related]

  • 7. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis.
    Block GA, Martin KJ, de Francisco AL, Turner SA, Avram MM, Suranyi MG, Hercz G, Cunningham J, Abu-Alfa AK, Messa P, Coyne DW, Locatelli F, Cohen RM, Evenepoel P, Moe SM, Fournier A, Braun J, McCary LC, Zani VJ, Olson KA, Drüeke TB, Goodman WG.
    N Engl J Med; 2004 Apr 08; 350(15):1516-25. PubMed ID: 15071126
    [Abstract] [Full Text] [Related]

  • 8. Early initiation of cinacalcet for the treatment of secondary hyperparathyroidism in hemodialysis patients: a three-year clinical experience.
    Lucchi L, Carboni C, Stipo L, Malaguti V, Ferrari F, Graziani R, Arletti S, Graziosi C.
    Artif Organs; 2011 Dec 08; 35(12):1186-93. PubMed ID: 21848793
    [Abstract] [Full Text] [Related]

  • 9. Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical Trial.
    Block GA, Bushinsky DA, Cheng S, Cunningham J, Dehmel B, Drueke TB, Ketteler M, Kewalramani R, Martin KJ, Moe SM, Patel UD, Silver J, Sun Y, Wang H, Chertow GM.
    JAMA; 2017 Jan 10; 317(2):156-164. PubMed ID: 28097356
    [Abstract] [Full Text] [Related]

  • 10. A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysis.
    Chonchol M, Locatelli F, Abboud HE, Charytan C, de Francisco AL, Jolly S, Kaplan M, Roger SD, Sarkar S, Albizem MB, Mix TC, Kubo Y, Block GA.
    Am J Kidney Dis; 2009 Feb 10; 53(2):197-207. PubMed ID: 19110359
    [Abstract] [Full Text] [Related]

  • 11. Impact of vitamin D dose on biochemical parameters in patients with secondary hyperparathyroidism receiving cinacalcet.
    Wilkie M, Pontoriero G, Macário F, Yaqoob M, Bouman K, Braun J, von Albertini B, Brink H, Maduell F, Graf H, Frazão JM, Bos WJ, Torregrosa V, Saha H, Reichel H, Zani VJ, Carter D, Messa P.
    Nephron Clin Pract; 2009 Feb 10; 112(1):c41-50. PubMed ID: 19365139
    [Abstract] [Full Text] [Related]

  • 12. Intravenous calcitriol for treatment of hyperparathyroidism in children on hemodialysis.
    Greenbaum LA, Grenda R, Qiu P, Restaino I, Wojtak A, Paredes A, Benador N, Melnick JZ, Williams LA, Salusky IB.
    Pediatr Nephrol; 2005 May 10; 20(5):622-30. PubMed ID: 15785941
    [Abstract] [Full Text] [Related]

  • 13. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L.
    Dan Med Bull; 2008 Nov 10; 55(4):186-210. PubMed ID: 19232159
    [Abstract] [Full Text] [Related]

  • 14. Cinacalcet: An oral calcimimetic agent for the management of hyperparathyroidism.
    Dong BJ.
    Clin Ther; 2005 Nov 10; 27(11):1725-51. PubMed ID: 16368445
    [Abstract] [Full Text] [Related]

  • 15. Relationship between reductions in parathyroid hormone and serum phosphorus during the management of secondary hyperparathyroidism with calcimimetics in hemodialysis patients.
    Cooper K, Quarles D, Kubo Y, Tomlin H, Goodman W.
    Nephron Clin Pract; 2012 Nov 10; 121(3-4):c124-30. PubMed ID: 23208191
    [Abstract] [Full Text] [Related]

  • 16. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis.
    Ross EA, Tian J, Abboud H, Hippensteel R, Melnick JZ, Pradhan RS, Williams LA, Hamm LL, Sprague SM.
    Am J Nephrol; 2008 Nov 10; 28(1):97-106. PubMed ID: 17914251
    [Abstract] [Full Text] [Related]

  • 17. Dose determination of cinacalcet hydrochloride in Japanese hemodialysis patients with secondary hyperparathyroidism.
    Akiba T, Akizawa T, Tsukamoto Y, Uchida E, Iwasaki M, Koshikawa S, KRN1493 Study Group.
    Ther Apher Dial; 2008 Apr 10; 12(2):117-25. PubMed ID: 18387159
    [Abstract] [Full Text] [Related]

  • 18. Effect of Cinacalcet and Vitamin D Analogs on Fibroblast Growth Factor-23 during the Treatment of Secondary Hyperparathyroidism.
    Sprague SM, Wetmore JB, Gurevich K, Da Roza G, Buerkert J, Reiner M, Goodman W, Cooper K.
    Clin J Am Soc Nephrol; 2015 Jun 05; 10(6):1021-30. PubMed ID: 25873267
    [Abstract] [Full Text] [Related]

  • 19. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease.
    Torres PU.
    J Ren Nutr; 2006 Jul 05; 16(3):253-8. PubMed ID: 16825031
    [Abstract] [Full Text] [Related]

  • 20. Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE study results.
    Fishbane S, Shapiro WB, Corry DB, Vicks SL, Roppolo M, Rappaport K, Ling X, Goodman WG, Turner S, Charytan C.
    Clin J Am Soc Nephrol; 2008 Nov 05; 3(6):1718-25. PubMed ID: 18945995
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 48.